Results 141 to 150 of about 53,350 (260)

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

CTSL loss leads to anti-PD-1 immunotherapy resistance in lung cancer by suppressing the anti-tumor function of peripheral CD8⁺ T cells. [PDF]

Front Immunol
Wang Y, Huang J, Zou X, Xu J.
europepmc   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source

Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer. [PDF]

Front Immunol
Kumar P, Ranmale S, Mehta S, Tongaonkar H, Maniar V, Mania-Pramanik J.   +5 more
europepmc   +1 more source

Black phosphorus‐based photothermal disruption of cancer‐associated fibroblast barriers and tumor‐associated macrophage targeting to enhance anti‐PD‐L1 immunotherapy in triple‐negative breast cancer

Interdisciplinary Medicine, EarlyView.
MBB modulates the TNBC tumor microenvironment by targeting TAM/CXCL1 and facilitates anti‐PD‐L1 therapy by disrupting CAF barriers via its photothermal effect. This combined strategy subsequently enhances the efficacy of PD‐L1 mAb and suppresses TNBC progression, metastasis, and recurrence.
Bo Pan, Shicui Hong, Xinyue Wang, Yanghang Li, Cai Wang, Yaxiao Liu, Ying Chen, Chen Fang, Yifeng Zheng, Shengqi Wang, Juping Zhang, Neng Wang, Zhiyu Wang   +12 more
wiley   +1 more source

Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers. [PDF]

Front Immunol
Hu Q, Sun Y.
europepmc   +1 more source

Osteoarthritis: An Immuno‐Inflammatory Disease‐Mechanisms of Immune Cell Dysregulation and Potential Therapeutic Strategies

Med Research, EarlyView.
This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei, Xiaoxian Lou, Xu Su, Shubao Liu, Yanli Tong, Jie Chen, Xuerui Chen, Wenjun Mao, Hui Yu, Liangbin Lin   +9 more
wiley   +1 more source

Novel insights into the histopathological characteristics of immune checkpoint inhibitor-related myocarditis. [PDF]

ESC Heart Fail
Nishikawa T, Otani T, Yamamoto H, Yasui T, Shingu M, Osumi Y, Ishibashi K, Ikeda Y, Nonaka A, Fukuda Y, Murai R, Furukawa Y, Hara S, Sawaki D, Hiranuma N, Ohashi Y, Takaya T, Asada Y, Ishii N, Kubo T, Kinugasa Y, Date E, Iizuka N, Sakamoto N, Kitai T, Izumi C, Amemiya K, Ohta-Ogo K, Nishihira K, Kinugasa M, Shimokawa T, Tamita K, Fujita M, Hatakeyama K.   +33 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Correction: Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. [PDF]

PLoS One
Calescibetta A, Dalton R, Fortenbery N, Ward G, Christiansen S, Chen X, Cheng P, Razabdouski T, Glode AJ, Tu N, Le Trinh T, Liu J, Wright KL, Wei S, Eksioglu EA.   +14 more
europepmc   +1 more source